EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synthetic single‐domain antibodies as immunoconjugate therapeutics

Robbins Puthenveetil, Aimen Zlitni, Wenting Zhang, Martin D Strain, Gilad Kaplan, Sujiet Puthenveetil, Asya Grinberg, Stanislas C Blein, Sayumi Yamazoe iD

FEBS Letters · 20.11.2026

DOI: 10.1002/1873-3468.70498 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift FEBS Letters, online erschienen am 20.11.2026. Verfasst von Robbins Puthenveetil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single‐domain antibodies (sdAbs) are emerging scaffolds for antibody–drug conjugates (ADCs) and radioconjugates (RCs). Their small size, modularity, and tunable pharmacokinetics enable alignment of binding, payload, and tumor exposure. This review examines synthetic sdAb library construction, engineering strategies, conjugation chemistry, payload selection, and alignment of target expression with pharmacokinetics and tumor delivery. Evidence from the literature indicates that stability‐engineered scaffolds and rationally curated diversity can improve solubility, aggregation resistance, and compatibility with site‐specific conjugation. Multivalent, multispecific, and half‐life‐extended formats broaden options. Future progress will depend on integrating molecular design with target biology to optimize efficacy and safety across payloads and radionuclides.

Schlagwörter

Stichwörter der Autor:innen

VHHantibody–drug conjugatesbiophysical optimizationradioconjugatessingle‐domain antibodies

Autor:innen und Institutionen

  • Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Oncology Targeted Discovery, R&D, AstraZeneca, Hamilton, Canada.
  • Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Sayumi Yamazoe

Zitieren

APA

Puthenveetil, R., Zlitni, A., Zhang, W., Strain, M. D., Kaplan, G., Puthenveetil, S., Grinberg, A., Blein, S. C., & Yamazoe, S. (2026). Synthetic single‐domain antibodies as immunoconjugate therapeutics. FEBS Letters. https://doi.org/10.1002/1873-3468.70498

Vancouver

Puthenveetil R, Zlitni A, Zhang W, Strain MD, Kaplan G, Puthenveetil S, et al. Synthetic single‐domain antibodies as immunoconjugate therapeutics. FEBS Letters. 2026. doi:10.1002/1873-3468.70498

BibTeX
@article{Puthenveetil2026,
  author = {Puthenveetil, Robbins and Zlitni, Aimen and Zhang, Wenting and Strain, Martin D and Kaplan, Gilad and Puthenveetil, Sujiet and Grinberg, Asya and Blein, Stanislas C and Yamazoe, Sayumi},
  title = {Synthetic single‐domain antibodies as immunoconjugate therapeutics},
  journal = {FEBS Letters},
  year = {2026},
  doi = {10.1002/1873-3468.70498}
}
Kostenlos starten →